Discover

FHTX
Foghorn Therapeutics Inc.
5.16
1 x 4.46
7 x 5.13
bid
ask
+
0.00
0.00%
3 @ 04:00 PM
5.00 -0.16 (3.10%)
Ytd-4.44%
1y-15.41%
day range
3.27
52 week range
6.95
OpenPrev Close5.16LowHighMkt Cap302.96M
Vol0.00Avg Vol241.11KEPS-1.16P/E-4.45Forward P/E-3.12
Beta2.86Short Ratio7.62Inst. Own72.09%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg4.47200-d Avg4.861yr Est12.00

FHTX News

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the anal

benzinga.com
Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For S

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Foghorn Therapeutics To Share New Cancer Drug Data At Major Research Conference

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new cl

benzinga.com
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform a

benzinga.com
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX)

benzinga.com
Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion

benzinga.com
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11

BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy

benzinga.com
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12

Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a

benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 838 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 1076 companies hit new 52-week lows.

benzinga.com
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.